Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23569903 | 1.00 | KRAS (0.38) | KRASSOS1 | |
| SCHEMBL23569912 | 1.00 | KRAS (0.38) | KRASSOS1 | |
| SCHEMBL23848832 | 0.87 | JAK3 (0.38) | KRASSOS1 | |
| SCHEMBL24462667 | 0.86 | JAK3 (0.37) | KRAS | |
| SCHEMBL22967692 | 0.85 | — | — | |
| SCHEMBL24611096 | 0.85 | JAK3 (0.36) | KRAS | |
| SCHEMBL23848396 | 0.84 | JAK3 (0.34) | — | |
| SCHEMBL25888590 | 0.83 | KRAS (0.35) | KRAS | |
| SCHEMBL23569909 | 0.83 | JAK3 (0.42) | — | |
| SCHEMBL23569910 | 0.83 | JAK3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787811-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230011726-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-11384087-B1 | — | — | 2022-07-12 | — | — | US | disclosed |
| US-20220213109-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| US-11345701-B1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11180506-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-11-23 | — | — | US | disclosed |
| US-11161847-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20210292331-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-09-23 | — | — | US | disclosed |
| WO-2021121367-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-06-24 | — | — | WO | disclosed |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2021-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | KRAS 1845/4885SOS1 2460/4885 |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | KRAS 1641/4885SOS1 2394/4885 |
| US-11161847-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 119/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 782/4885 |
| US-20230011726-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 101/4885 |
| US-11180506-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 101/4885 |
| US-11384087-B1 | — | KRAS, NRAS, APC | KRAS 1/4885SOS1 198/4885 |
| US-11345701-B1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 119/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 782/4885 |
| US-11787811-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 101/4885 |
| US-20220213109-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 101/4885 |
| US-20210292331-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KRAS 1/4885SOS1 101/4885 |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 320/4885 |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.